Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes
Lyon, 69677, France
Location status: Recruiting
NCT Number: NCT05772611
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Lyon, 69677, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.
Time frame: Through study completion, an average of 1year
This measure will compare the result of immunological and genetic makers with clinical data of each patient.
Contact information is provided by the study sponsor or research team.
Jerome HONNORAT, MD
CONTACT
Marine VILLARD, RCA
CONTACT
Hospices Civils de Lyon
Other
Acronym: Car-Te-Cell
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05783947
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bron, France
View Trial DetailsNCT05728931
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Lyon, France
View Trial DetailsNCT04708626
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Uppsala, Uppland, Sweden
View Trial DetailsNCT07653984
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Guangzhou, Guangdong, China
View Trial Details